...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Vote reminder

"Is that too much to expect from Zenith leadership?  Chicagoest yes it is too much to ask from DM and co based on the past 18 years history ....   If there is a major change in management or a  new large BP partnership , buyout or license deal than I will start to get excited. Just having positive trial data from Zenith at this point is not enough plus an IPO would be quite nice to go along  with a BP deal .. Hoping for something BIG but not expecting much at all from Thursday AGM

Share
New Message
Please login to post a reply